Hwa An Announces Signing of Technology and Patent Application Rights Assignment Agreement with Subsidiary Yuan Hwa SmartMed Co., Ltd.

1. Date of Event: July 8, 115 2. Contracting Party: Yuan Hwa SmartMed Co., Ltd. 3. Relationship with Company: Subsidiary wholly owned (100%) by the Company 4. Contract Effective Date (or Termination/Rescission Date): July 8, 115 5. Main Content (Not applicable for rescission): The Company has entered into a Technology and Patent Application Rights Assignment Agreement with its subsidiary, Yuan Hwa SmartMed Co., Ltd. The Company will assign to Yuan Hwa SmartMed its proprietary technology, confidential information, know-how, and patent application rights related to the 'USE OF BREMELANOTIDE FOR THE TREATMENT OF VITILIGO' (Bremelanotide for treating vitiligo). In partial consideration for this assignment, Yuan Hwa SmartMed will issue 4,500,000 ordinary shares, each with a par value of NT$10, to the Company. Additionally, the parties may separately agree in writing on milestone-based bonuses as additional consideration and their triggering conditions. 6. Restrictive Clauses (Not applicable for rescission): As stipulated in the contract. 7. Commitments (Not applicable for rescission): None 8. Other Material Agreements (Not applicable for rescission): None 9. Impact on Company's Financial and Business Operations: The Company's proprietary technology, know-how, and patent application rights for treating vitiligo possess significant market potential. The Company anticipates that this assignment will have a positive impact on its future financial and business performance. 10. Specific Purpose: Based on the overall operational planning of the Hwa An Group. 11. Other Matters to be Disclosed: New drug development involves long timelines, high investment costs, and no guarantee of success, which may pose risks to investors. Investors should exercise careful judgment and invest prudently.